DBV Technologies Provides Update on Investigational Viaskin Peanut for Children Ages 4-11 Years - Seite 3
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the design of DBV’s anticipated clinical trials, the anticipated timeline for regulatory
submissions and trial initiation, potential future interactions with the FDA, the potential benefits of Viaskin Peanut DBV’s continued development of epicutaneous immunotherapy the
implementation of DBV’s global restructuring plan, potential cost savings anticipated from the global restructuring plan, and DBV’s forecast of its cash runway. These forward-looking statements and
estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the Company’s products have not been authorized for sale in any country. Among the factors
that could cause actual results to differ materially from those described or projected herein are risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as
to DBV’s ability to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties associated generally with research and development, clinical
trials and related regulatory reviews and approvals; risks related to whether results from a clinical trial will be predictive of the results of future trials; the risk that trials and studies may
be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of DBV’s product candidates; expectations for regulatory approvals to conduct trials or
to market products; and DBV’s ability to successfully execute on its restructuring plans. Furthermore, the timing of any action by any regulatory agency cannot be guaranteed, particularly in light
of the COVID-19 pandemic. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in
this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers, DBV’s Securities and Exchange Commission filings and reports, including in the Company’s
Annual Report on Form 20-F for the year ended December 31, 2019, and future filings and reports by DBV. Existing and prospective investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the
information contained in this Press Release.